256 related articles for article (PubMed ID: 37760506)
1. Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.
Abusalem M; Martiniova L; Soebianto S; DePalatis L; Ravizzini G
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760506
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
4. The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.
Martiniova L; Zielinski RJ; Lin M; DePalatis L; Ravizzini GC
Cancer J; 2022 Nov-Dec 01; 28(6):446-453. PubMed ID: 36383907
[TBL] [Abstract][Full Text] [Related]
5. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
[TBL] [Abstract][Full Text] [Related]
7. Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives.
Lin M; Ta RT; Kairemo K; Le DB; Ravizzini GC
Cancer Biother Radiopharm; 2021 Apr; 36(3):237-251. PubMed ID: 32589458
[TBL] [Abstract][Full Text] [Related]
8. Toward the Discovery and Development of PSMA Targeted Inhibitors for Nuclear Medicine Applications.
Pastorino S; Riondato M; Uccelli L; Giovacchini G; Giovannini E; Duce V; Ciarmiello A
Curr Radiopharm; 2020; 13(1):63-79. PubMed ID: 31362683
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
10. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
[TBL] [Abstract][Full Text] [Related]
12. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
13. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
14. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
15. PET/CT With
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2018; 11(1):4-13. PubMed ID: 29090673
[TBL] [Abstract][Full Text] [Related]
16. Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends.
Kaewput C; Vinjamuri S
J Clin Med; 2022 May; 11(10):. PubMed ID: 35628867
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.
Diao W; Cai H; Chen L; Jin X; Liao X; Jia Z
Curr Top Med Chem; 2019; 19(1):33-56. PubMed ID: 30706785
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]